
Sign up to save your podcasts
Or


Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers.
CME information and select publications here.
By Dr. Neil Love4.4
6262 ratings
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers.
CME information and select publications here.

141 Listeners

319 Listeners

500 Listeners

32 Listeners

75 Listeners

14 Listeners

17 Listeners

13 Listeners

0 Listeners

118 Listeners

58 Listeners

291 Listeners

3,355 Listeners

198 Listeners

510 Listeners

58 Listeners

190 Listeners

0 Listeners